Acotiamide
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
Trade names | Acofide (JP) |
Routes of administration |
By mouth (tablets) |
ATC code | None |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 84.21–85.95% |
Metabolism | UGT1A8 and 1A9 (major) |
Biological half-life | 10.9–21.7 hours |
Excretion | Feces (92.7%), urine (5.3%)[1] |
Identifiers | |
|
|
CAS Number | 185106-16-5 |
PubChem (CID) | 5282338 |
ChemSpider | 4445505 |
UNII | D42OWK5383 |
KEGG | D08838 |
ChEMBL | CHEMBL2107723 |
Chemical and physical data | |
Formula | C21H30N4O5S |
Molar mass | 450.55 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) (verify) |
Acotiamide (brand name Acofide, codenamed YM-443 and Z-338) is a drug approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.[2] It acts as an acetylcholinesterase inhibitor.
References[edit]
- ^ "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
- ^ Matsueda, K; Hongo, M; Tack, J; Aoki, H; Saito, Y; Kato, H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients withfunctional dyspepsia – 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility: The Official Journal of the European Gastrointestinal Motility Society. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698.
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
This article about an amine is a stub. You can help Wikipedia by expanding it. |